Navigation Links
Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced its financial results for the first quarter ended March 31, 2009. Optimer reported a net loss for the first quarter of 2009 of $10.9 million, or $0.36 per share which was in line with the Company's expectations. This compares to a net loss for the first quarter of 2008 of $7.9 million, or $0.28 per share. Research and development expenses in the first quarter of 2009 were $8.8 million compared to $6.9 million in the first quarter of 2008. The increase is primarily due to an increase in clinical development and regulatory expenses related to Optimer's fidaxomicin and prulifloxacin programs.

As of March 31, 2009, Optimer held cash, cash equivalents and short-term investments of $62.6 million.

"We are off to a strong start in 2009," said Michael N. Chang, Ph.D., Optimer's President and CEO. "We announced plans to prepare a marketing application in Europe based on the results of the first fidaxomicin Phase 3 trial for Clostridium difficile infection. We also reported positive top-line results from the second prulifloxacin Phase 3 trial for the treatment of infectious diarrhea."

Recent Corporate Highlights

  • Announced plans to prepare a Marketing Authorization Application (MAA) for submission with the European Medicines Agency (EMEA) for approval of fidaxomicin as an oral treatment for Clostridium difficile infection (CDI) based on the results from the Company's first Phase 3 fidaxomicin trial.
  • Production patent for fidaxomicin issued by the United States Patent and Trademark Office.
  • Announced positive results from the second pivotal Phase 3 trial of prulifloxacin for the treatment of infectious diarrhea. The tri
    '/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
3. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
4. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
5. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
6. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
7. Idenix Pharmaceuticals Reports First Quarter Financial Results
8. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
9. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
10. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
11. Vanda Pharmaceuticals Reports First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015   SurePure, Inc ... photopurification, announced today that the Company has completed ... continued trading of SurePure ("SURP") securities on OTCQB, ... for entrepreneurial and development stage companies. ... standards and eligibility requirements designed to improve marketplace ...
(Date:3/27/2015)... ROCKVILLE, Md. , March 27, 2015  CASI ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a commercial focus on ... the three and 12 months ended December 31, 2014.  ... of ($1.6 million), or ($0.05) per share, for the ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... after dealing with certain matters, including the appointment of ... on March 26, 2015 (the "Meeting") was adjourned, as ... 2015 at 11:00 a.m. ( Toronto ... changed from that previous disclosed. The Meeting will reconvene ...
(Date:3/26/2015)... 2015 Neogen Corporation (NASDAQ: NEOG ) ... quarter of fiscal 2015, which ended Feb. 28, increased ... $6,575,000. Earnings per share in the current quarter were ... net income increased 17% over prior year to $24,142,000, ... per share, for the same period a year ago. ...
Breaking Biology Technology:SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6SQI Diagnostics Inc. Announces Adjournment of Meeting 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... America,s war on terror includes fighting the dark ... chemist Dr. Frank Raushel is helping with the fight ... chemical agent, the organophosphates. , Synthetic organophosphates started their ... their way into the dangerous alleys of chemical warfare ...
... away, but soccer aficionados can get an early start ... National Institute of Standards and Technology (NIST) and the ... summer. , Nanosoccerthe Lilliputian competition where computer-driven "nanobots" the ... no bigger than a grain of ricewill be part ...
... SAN DIEGO, Nov. 13 Gen-Probe Incorporated,(Nasdaq: GPRO ... the Lazard,Capital Markets 5th Annual Healthcare Conference on Tuesday, ... presentation is scheduled,to be webcast live and may be ... website at http://www.gen-probe.com . The webcast,will be available ...
Cached Biology Technology:Researcher working on destruction of chemical weapons 2Let the games begin! Nanosoccer at 2009 RoboCup in Austria 2Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference 2
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
(Date:3/12/2015)... 12, 2015 Beta Systems ... and access management (IAM) solution for a fixed ... Beta System,s new IAM package, customers benefit from ... from multiple IAM implementations across different industries. The ... well as any necessary services and consulting. It ...
(Date:3/11/2015)... --  The Sync Project™ today announced the ... harness music to improve health. The platform maps ... of physiology, enabling the study of the therapeutic ... It is designed for medical and health research, ... and accelerate the discovery of the clinical applications ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... Reserve researchers have identified a genetic factor that blocks ... attacks, strokes and other potentially life-threatening events. ... latest in a string of discoveries from the laboratory ... a remarkable genetic family. Kruppel-like factors appear to play ...
... Sept. 4, 2013   MedNet Solutions , a global ... systems, is pleased to announce its sponsorship of, participation ... September 10-13 in Chicago .  MedNet ... leading conference...the largest and most prestigious clinical data management ...
... New technology for discovering antibiotics, anti-cancer drugs and other medicines ... treasure hunt that already has given humanity more than 50 ... is the topic of the cover story in Chemical ... Chemical Society. Lisa M. Jarvis, C&EN senior editor, points ...
Cached Biology News:Researchers discover a new pathway in blood vessel inflammation and disease 2MedNet Solutions To Sponsor The SCDM Annual Conference For The Eighth Straight Year 2
... the things youll be telling others after you ... Erica Golemis, One look at the table of ... in protein interaction will tell you immediately that ... part of your personal protein chemistry library. You ...
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic gel acid stain has also found ... bandshift assays. One mL stains 100 minigels. A ...
Synonym: modified Grace's Insect medium...
... a 12 amino acid synthetic peptide whose sequence is derived ... is (amino to carboxy terminus): C - S(338) - ... Q - V - A - P - A(348). ... experiments with the polyclonal antibody that reacts with this product ...
Biology Products: